Enovis Corporation (NYSE:ENOV) Given Average Recommendation of “Moderate Buy” by Brokerages

Enovis Corporation (NYSE:ENOV) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $41.7143.

Several equities research analysts recently commented on the stock. BMO Capital Markets assumed coverage on shares of Enovis in a research note on Wednesday, July 8th. They set an “outperform” rating and a $29.00 price target on the stock. Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research report on Wednesday, July 8th. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Enovis in a report on Friday, May 22nd. Finally, Wells Fargo & Company decreased their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert bought 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders purchased 4,200 shares of company stock valued at $92,084 over the last three months. 2.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ENOV. AQR Capital Management LLC raised its holdings in shares of Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after buying an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares during the period. Empowered Funds LLC grew its holdings in shares of Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Finally, Amundi increased its position in Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Performance

Shares of Enovis stock opened at $26.12 on Friday. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. Enovis has a 52 week low of $19.14 and a 52 week high of $34.28. The firm’s 50 day moving average is $23.60 and its two-hundred day moving average is $23.76. The firm has a market capitalization of $1.50 billion, a P/E ratio of -1.31 and a beta of 1.39.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the previous year, the firm earned $0.81 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis will post 3.12 EPS for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.